GLP-1 drugs are being investigated by the FDA for possible side effects
People taking these medications had a lower risk of suicidal thoughts compared with older drugs in U.S. studies
Semaglutide, an active ingredient in GLP-1 drugs like Ozempic and Wegovy has no link with suicidal ideation according to a large new study
Suicidal ideation, hair loss and aspiration have been reported as potential side effects of GLP-1 drugs
The Food and Drug Administration (FDA) is currently investigating possible side effects from GLP-1 drugs, including suicidal ideation, hair loss, and aspiration. These medications have become popular for both weight loss and type 2 diabetes treatment over the last year. The FDA investigation comes after a large new study found no link between semaglutide, an active ingredient in GLP-1 drugs like Ozempic and Wegovy, and suicidal ideation. However, people taking these medications had a lower risk of suicidal thoughts compared with older drugs in U.S. studies.
The FDA is investigating reports of severe side effects tied to weight loss injectables.
Over a short amount of time, diabetes and weight loss injectable drugs Wegovy, Ozempic, and Mounjaro among others have become wildly popular.
These drugs help treat underlying issues, so if you don't have those underlying issues in terms of glucose management, you're more liable to have negative side effects that are typically associated with these medications.
Without the proper prescription, consumers should also beware of knock-off injectables on the market and injectables that compound the drugs.
Accuracy
Some health officials and even pharmaceutical companies are stressing the importance of properly using these drugs.
Without the proper prescription, consumers should also beware of knock-off injectables on the market and injectables that compound the drugs.
A lot of people are adding or adulterating the mixture with B-12 and other weight loss supplements, which is not FDA approved.
Deception
(30%)
The article is deceptive in several ways. Firstly, the author implies that weight loss injectables are easy to get your hands on when they are actually in short supply. Secondly, the author suggests that some people might be taking these drugs without needing them which is not true as these medications are indicated for serious diseases and should only be used under medical supervision. Thirdly, the article quotes Dr Sahar Takkouche from Vanderbilt University Medical Center who states that weight loss injectables can have negative side effects if they are not prescribed properly or if consumers take them without proper medical need. However, this statement is misleading as it implies that these medications are safe when used for cosmetic purposes which is not true.
The article suggests that some people might be taking these drugs without needing them
The author implies that weight loss injectables are easy to get your hands on
Fallacies
(75%)
The article contains several examples of informal fallacies. The author uses an appeal to authority by citing statements from health officials and pharmaceutical companies without providing any evidence or context for their claims. Additionally, the author presents a dichotomous depiction of weight loss injectables as either safe and effective or dangerous and harmful, which oversimplifies complex issues related to medical treatments. The article also contains inflammatory rhetoric by presenting negative side effects associated with these medications in sensationalized language.
Lilly Stands Against the Use of its Medicines for Cosmetic Weight Loss: Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for cosmetic weight loss.
The way that these drugs work is they help treat underlying issues, so if you don't have those underlying issues in terms of glucose management, you're more liable to have negative side effects that are typically associated with these medications.
On top of that, without the proper prescription, consumers should also beware of knock-off injectables on the market,
Bias
(80%)
The article contains examples of religious bias and monetary bias. The author uses language that depicts the use of weight loss injectables as a sinful act, which is an example of religious bias.
> They’re not easy to get your hands on because a lot of the drugs are in short supply. However, officials said some people are even taking the drug when they might not need it.
Site
Conflicts
Of
Interest (50%)
Kori Johnson has a conflict of interest with Eli Lilly as they are the manufacturer of Ozempic and Mounjaro which are weight loss injectables that she is reporting on.
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of weight loss injectables as they are reporting on negative side effects and discussing multiple drugs in this category. The article also mentions Eli Lilly which is a company that produces one of these drugs.
People taking the popular diabetes and obesity drugs Ozempic and Wegovy had a lower risk of suicidal thoughts than those taking other medications to treat the same conditions
The research found that people taking semaglutide had a 49%to 73%lower risk of first-time or recurring suicidal thoughts than those taking another drug for those conditions during a six-month follow-up period.
People prescribed semaglutide for weight loss had a 0.11%risk of first-time suicidal ideations and approximately a 7%risk of recurrent suicidal ideation .That's compared to 0.43%and 14%, respectively, for the group prescribed other weight-loss medications.
Accuracy
The FDA is investigating reports of severe side effects tied to weight loss injectables.
GLP-1 medications increase in popularity for weight loss but have become popular over the last year for type 2 diabetes treatment as well.
Deception
(50%)
The article is deceptive in that it presents the results of a study as evidence that Ozempic and Wegovy are not linked to an increase in suicidal thoughts when there is no causal association between these drugs and suicide. The article also fails to disclose sources, which violates one of the ignore rules.
The headline claims that taking Novo Nordisk's Ozempic or Wegovy is not tied to an increase in suicidal thoughts. However, this claim is misleading as there is no causal association between these drugs and suicide.
Fallacies
(90%)
The article contains several examples of an appeal to authority fallacy. The author cites a study funded by the U.S. National Institutes of Health as evidence that taking Ozempic or Wegovy is not linked to an increase in suicidal thoughts, without providing any information about the methodology or reliability of the study.
The article states that 'a large U.S. study found no evidence that taking Novo Nordisk's Ozempic or Wegovy is tied to an increase in suicidal thoughts.'
The author cites a study funded by the U.S. National Institutes of Health as evidence without providing any information about its methodology or reliability.
Bias
(85%)
The article reports that a study found no evidence linking the use of Ozempic or Wegovy to an increase in suicidal thoughts. However, it also mentions European and U.S. regulators looking into anecdotal reports that people taking semaglutide had thoughts of self-harm, which could be seen as a form of bias towards the drug's safety.
The article mentions European and U.S. regulators looking into anecdotal reports that people taking semaglutide had thoughts of self-harm.
The article states that a study found no evidence linking the use of Ozempic or Wegovy to an increase in suicidal thoughts.
The Food and Drug Administration (FDA) is investigating possible side effects from GLP-1 drugs, including suicidal ideation, hair loss, and aspiration.
GLP-1 medications increase in popularity for weight loss but have become popular over the last year for type 2 diabetes treatment as well.
The FDA investigation is not the first time an association between suicidal ideation and GLP-1 medications has been reviewed. The European Medicines Agency (EMA) began investigating this potential side effect in July 2023.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(85%)
The article discusses the potential side effects of GLP-1 drugs such as suicidal ideation and hair loss. The FDA is investigating these reports, but new research shows no link between semaglutide (the active ingredient in certain GLP-1 medications) and suicidal thoughts. However, previous research has shown that potential side effects of GLP-1 medications include gastrointestinal issues such as nausea and vomiting, increased heart rate, and an increased risk for pancreatitis and gastroparesis. Despite the possible side effects, GLP-1 drugs are considered safe. The article also discusses a recent study funded by the National Institutes of Health (NIH) that concluded there was no evidence that GLP-1 drugs containing semaglutide cause suicidal thoughts.
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (50%)
Corrie Pelc has a conflict of interest on the topics of GLP-1 drugs and weight loss medications as she is reporting on Ozempic, Wegovy, Mounjaro and other GLP-1 medications. She also reports on companies that manufacture these medications.
Corrie Pelc has a financial interest in the pharmaceutical industry as she works for Medical News Today which covers topics related to health and medicine.
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topics of GLP-1 drugs and weight loss medications as they are manufactured by companies that have financial ties to the Food and Drug Administration. The article also mentions suicidal ideation as a potential side effect of these medications.
